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Key Points: 
1. Pro-inflammatory megakaryocytes from mice with Gray Platelet Syndrome drive the 
extension of myelofibrosis, splenomegaly and emperipolesis. 
2. The lack of pre-formed alpha-granules in Nbeal2-/- platelets leads to protection against 
cancer metastasis. 
 
 
Abstract  
NBEAL2 encodes a multidomain scaffolding protein with a putative role in granule ontogeny 
in human platelets. Mutations in NBEAL2 underlie Gray Platelet Syndrome (GPS), a rare 
inherited bleeding disorder characterized by a lack of α-granules within blood platelets and 
progressive bone marrow fibrosis. We present here a novel Nbeal2-/- murine model of GPS 
and demonstrate that the lack of α-granules is due to their loss from platelets/mature 
megakaryocytes, and not by initial impaired formation. We show that the lack of Nbeal2 
confers a pro-inflammatory phenotype to the bone marrow megakaryocytes, which in 
combination with the loss of proteins from α-granules drives the development of bone 
marrow fibrosis. In addition, we demonstrate that α-granule deficiency impairs platelet 
function beyond their purely hemostatic role and that Nbeal2 deficiency has a protective 
effect against cancer metastasis. 
  
 3
Introduction  
Platelets are anucleate cells that circulate in the blood and their primary role is in hemostasis. 
They are also essential in processes such as inflammation 1, angiogenesis 2, and wound 
healing 3 and contribute to the pathogenesis of myocardial infarction, stroke 4, rheumatoid 
arthritis 5, and malignant metastasis 6,7. This myriad of actions is explained in part by the 
unique cargo of their alpha (α) and dense (δ) granules.  A vast array of more than 300 
proteins is stored in the α-granules8 including hemostatic and adhesive molecules, such as 
von Willebrand Factor (VWF), fibrinogen and other coagulation factors, inflammatory 
peptides like IL1B, TGFB, RANTES and pro- and anti-angiogenic factors such as VEGF, 
PDGF, PF4 and THBS1 9.  
Platelets contain 30-50 α-granules which account for approximately 10% of their volume 9. 
Alpha-granules are formed early during megakaryopoiesis by the fusion of small vesicles 
from the trans-Golgi network and endocytic vesicles into multivesicular bodies (MVBs) 10 
then transported through the cytoplasmic extensions of the proplatelet shafts of the mature 
megakaryocytes (MKs), the bone-marrow residing platelet precursors, where they become 
trapped in the terminal buds, i.e. the nascent platelets 11,12.   
Gray platelet syndrome (GPS), is a rare autosomal recessive bleeding disorder first reported 
in 1970 13 caused by mutations in NBEAL2 14-16.  Platelets from GPS patients are large and 
have a gray appearance caused by an almost complete absence of α-granules. However some 
platelets contain MVBs and occasionally platelets with sparse α-granules are seen 17. Other 
organelles such as mitochondria, δ-granules and lysosomes are unaffected 18. Interestingly 
nearly all GPS cases develop fibrosis of the bone marrow in the fourth to fifth decade of life 
18
 possibly as a consequence of the steady release of cytokines, chemokines and growth 
factors normally packaged in the α-granules. 
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NBEAL2 belongs to a family of genes encoding the BEACH-domain containing proteins 14. 
Most of these genes encode large multidomain scaffolding proteins with at least 2,500 amino 
acids. Besides NBEAL2 and GPS, mutations in other members of this family are also 
causative of Mendelian disorders of granule ontogeny and the control of cell volume, with 
mutations in LYST causing abnormal lysosomal granules and large neutrophils in Chediak-
Higashi Syndrome 19, and a mutation in NBEA causing a defect of platelet δ-granules in a 
case with extreme autism 20.  
To study the role of Nbeal2 in α-granule formation and GPS-related pathologies, such as 
myelofibrosis, we generated Nbeal2 null (Nbeal2-/-) mice. We demonstrate that this murine 
model recapitulates the typical platelet phenotype observed in GPS patients including 
splenomegaly and myelofibrosis. Analysis of the MKs unexpectedly showed that α-granules 
are generated but not retained within MKs. We also show a strong pro-inflammatory 
transcriptome signature in MKs from Nbeal2-/- mice and interestingly platelets formed by 
these MKs lack the ability to support metastasis of melanoma cancer cells to the lung. In 
conclusion, we demonstrate for the first time that deficiency in Nbeal2 and a lack of α-
granules in GPS platelets has consequences beyond their primary role in haemostasis. 
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Materials and Methods  
 
Generation of Nbeal2-/- mice 
Gene targeting for Nbeal2 was performed as part of an international consortium 
(www.knockoutmouse.org) as previously reported 21-23, and described in Supplemental 
Methods, and illustrated in Suppl Fig 1A-B.  
Adult animals ranging 4-12 months were used including age-matched controls of the same 
genetic background. Mice were kept in specific pathogen-free conditions, and all procedures 
were performed according to the United Kingdom Home Office regulations. A minimum of 5 
different mice per experiment was used unless otherwise stated. 
 
Platelets and MKs isolation and analysis 
Blood was withdrawn from the IVC in either EDTA (5mM final) or ACD (111 mM glucose, 
71 mM citric acid, 116 mM sodium citrate) as anticoagulants depending on the experiment. 
Full blood counts were obtained using a Scil Vetabc instrument (Montpellier, France) and 
blood smears were stained with a May-Grünwald Giemsa (Romanovsky) stain. 
Platelet preparation, culture of bone marrow derived MKs, proplatelet assays, flow cytometry 
analysis and generation of cell lysates for western blot have been described before and are 
detailed elsewhere 24 and in Supplemental Methods. 
 
Transmission electron microscopy of platelets, bone marrow megakaryocytes and in 
vitro-cultured megakaryocytes 
Fixed solutions of platelets, bone marrow-derived and cultured MKs were rinsed in 0.1M 
HEPES buffer 5 times and processed as described in Supplemental Methods.  
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Immunostaining of platelets and megakaryocytes 
Fixed platelets were incubated onto coverslips at 37 ºC for 90 min. Purified cultured MKs 
were adhered onto fibrinogen-coated slides and then fixed. A detailed description of 
immunostaing is provided elsewhere 25 and in Supplemental Methods. 
 
Analysis of tissue sections 
Humerus, femur, tibia, fibula and spleen were taken and placed in a formalin fixative. After 
decalcification they were processed as stated in Supplemental Methods.  
 
Expression arrays and Q-PCR in cultured MKs 
RNA was isolated from cultured MKs using the RNeasy kit (Qiagen, Manchester, UK) and 
cDNA made using Superscript III or SS VILO (first Strand kit; Invitrogen). Q-PCR assays 
were performed on a Mx3005P qPCR System (Agilent Technologies, UK) using primers 
described in Suppl File 1. Expression levels were assayed using Illumina Mus 6v2 expression 
chip. Data processing and analysis were performed as described elsewhere 24. Gene set 
enrichment analysis was carried out using GSEA 26. Version 4 gene sets of GO molecular 
function were used with a weighted scoring scheme of the t scores.  
 
Experimental metastasis assay 
Murine metastatic melanoma B16-F10 cells were cultured in DMEM supplemented with 10% 
(v/v) fetal bovine serum, 2 mM glutamine and 100U/mL penicillin/streptomycin. Cells in log-
phase growth were harvested, resuspended in PBS and 5 × 105 cells (in 0.1 mL) were injected 
into the tail vein of 6-8 week old sex-matched syngeneic control (n=9) and Nbeal2-/- (n=5) 
mice. Additional groups included Nbeal2-/- animals (n=4) transfused with 240 x106 platelets 
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previously isolated from control mice, or PBS (n=3) and control mice injected with PBS 
(n=5) four hours prior to the melanoma cells injection. Mice were sacrificed 10 days later. 
Lungs were removed, rinsed in PBS and the number of metastatic foci counted under a 
dissecting microscope.  
 
Statistics 
Results are shown as Mean ± SEM. Statistical analysis was performed using the unpaired 
Student’s t test. P-values under 0.05 were considered statistically significant. 
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Results  
 
The Nbeal2-/- mouse has a Gray Platelet Syndrome phenotype 
The absence of Nbeal2 at transcript and protein level was confirmed in Nbeal2tm1a Wtsi/tm1a Wtsi 
(hereafter referred to as Nbeal2-/-) bone marrow-derived MKs and blood platelets (Fig 1A and 
1B). The platelet count was reduced by almost 50% (1,377±84 x103 vs 811±49 x103 
platelets/μL for control and Nbeal2-/- animals, respectively; P-value=3.1x10-7) (Fig 1C) and 
the mean platelet volume was increased (5.2±0.1 vs 6.1±0.1 fL; P-value=8.1x10-8) (Fig 1D), 
also shown by flow cytometric analysis (Fig 1E), and the “greyish” appearance confirmed 
(Fig 1F). Crucially, splenomegaly and bone marrow myelofibrosis, clinical features typical of 
GPS cases, were observed in Nbeal2-/- animals older than 9 months (Fig 1G and 1H, 
respectively). 
 
Nbeal2-/- platelets lack α-granules 
Platelet ultrastructure was studied by transmission electron microscopy (TEM). Control 
platelets had the typical discoid shape and contained numerous α-granules (Fig 2A-B). As 
expected platelets from Nbeal2-/- animals were larger, rounder in shape with some platelets 
showing abnormal membrane formations with linear or tubular sheets inclusions (Fig 2C-D 
and Suppl Fig 2). As in human GPS platelets, there was a reduction in α-granule contents. 
The typical vacuole-like organelles were present, with some containing electro-dense 
material (Fig 2C-D). The TEM results were confirmed by immunofluorescence staining for 
α-granule proteins (such as VWF) by confocal microscopy. VWF was shown to have the 
typical granular distribution in control platelets (Fig 2E) whereas Nbeal2-/- platelets either 
completely lacked VWF (Fig 2F) or displayed a diffuse rather than granular distribution. 
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Total platelet protein content was analysed by Western Blotting using platelet lysates. Whilst 
CD63 (LAMP-3), a marker of δ−granules and lysosomes, was present at similar levels in 
control and Nbeal2-/- platelets, there was a significant reduction in α-granule proteins such as 
VWF, THBS1 and PF4 in the latter (Fig 2G). 
We went on to characterize platelet function. First, we carried out flow cytometry analysis to 
assess the expression of the main platelet receptors on the surface of resting platelets, which 
showed no differences between groups of control and Nbeal2-/- mice for integrin αIIbβ3 
(CD41/61), integrin α2 (CD49b), glycoprotein (GP) V (CD42d) and GPVI (Suppl Fig 3). 
Engaging platelets with cross-linked collagen-related peptide (CRP) and thrombin showed 
equivalent levels of activation between groups of animals as determined by the level of 
fibrinogen binding to αIIbβ3 (Fig 2H top panel), consistent with preservation of the major 
platelet activation pathways. In contrast, exposure of the α-granule membrane protein P-
selectin on the outer surface of platelets after their activation with CRP and thrombin was 
significantly reduced in Nbeal2-/- mice (Fig 2H middle and bottom panels), consistent with 
the reduction in α-granules. 
 
Nbeal2-/- MKs have a maturation defect but proplatelet formation is maintained 
Bone marrow sections from Nbeal2-/- and control mice (n=5) were stained with haematoxylin 
and eosin (H&E) and an immunoperoxidase method for the platelet glycoprotein αIIbβ3 
complex (CD41). The number and morphology of the MKs in the bone marrow sections were 
assessed by a haemato-pathologist who was blinded to the Nbeal2 status of the mice (Fig 
3A). The total number of MKs was comparable in Nbeal2-/- and control mice (Fig 3B, top 
panel). However, Nbeal2-/- mice had significantly fewer large MK with multilobated nuclei 
(Fig 3B, middle panel; P-value=0.038) and an increase in small MKs with reduced nuclear 
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lobation compared with control mice (Fig 3B, bottom panel; P-value=0.00023). Further, the 
MKs in Nbeal2-/- mice had prominent emperipolesis of neutrophils (Fig 3A); this was not 
seen in MKs of the control samples. These distinctive MK morphological features enabled all 
Nbeal2-/- and control mice to be identified with 100% accuracy. To further study the potential 
effects of emperipolesis on MKs, including cell death, immunolabelling of Bcl-XL and 
cleaved caspase 3 was carried out in bone marrow sections. No difference was observed for 
either staining between control and Nbeal2-/- MKs (Suppl Fig 4). 
We then analysed in vitro MK differentiation and maturation from bone marrow cultures 
using two sub-maximal concentrations of thrombopoietin (TPO; 1 and 5 ng/mL) at two time 
points (3 and 5 days). The number of megakaryocytic CD41+ cells was similar in control and 
Nbeal2-/- samples at day 1. However, the difference in the percentage of CD41+ cells between 
control and Nbeal2-/- samples gradually increased up to 2.5-fold at day 5 with 5 ng/mL TPO 
(Fig 3C). In contrast, the proportion of high ploidy MKs (cells with 8N and above) within the 
CD41+ population did not differ between the cultures (Fig 3D). 
Proplatelet formation was analysed by adhering bone marrow-derived cultured MKs onto 
fibrinogen after selection of the most mature MKs (≥8N) over a BSA gradient. The rate of 
proplatelet formation was similar in control and Nbeal2-/- cells (Fig 3E).  
 
Lack of Nbeal2 does not affect α-granule formation, packaging or transport to the 
budding proplatelets 
TEM assessment of bone marrow culture-derived MKs showed no major differences between 
Nbeal2-/- cells and controls (Fig 4A-B). In particular there were equal numbers of MVBs, the 
precursors of α-granules, in both sample sets (Fig 4C-D). As only a few truly mature α-
granules were seen in the cultured MKs, we went on to study MKs directly flushed from the 
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bone marrow. Control MKs showed a well-defined demarcation membrane system (DMS) 
with the presence of “platelet territories” and mature α-granules (Fig 4E, G, I). Nbeal2-/- MKs 
appeared to have a more rudimentary DMS and a minor degree of vacuolisation but did not 
show any significant abnormalities such as membrane inclusions (Fig 4F, H, J, K, L). 
Strikingly, mature α-granules were present in Nbeal2-/- MKs and were of similar size and 
morphology to those in control MKs, although their density and opacity was slightly 
decreased (Fig 4G-J). The striking emperipolesis documented by light microscopy on bone 
marrow sections was also observed in Nbeal2-/- MKs by TEM (Suppl Fig 5). The presence of 
α-granules in both control and Nbeal2-/- MKs was confirmed by immunohistochemistry. 
Staining from VWF showed a similar granular distribution in both sets of samples (Suppl Fig 
6). In keeping with these observations, western blot analysis of Nbeal2-/- and control cultured 
MK lysates confirmed similar cellular content not only for CD63, but also for α-granule 
proteins such as VWF, THBS1 and PF4 (Fig 4M). 
The apparent discrepancy of these results between the Nbeal2-/- platelets and MKs led us to 
assess whether the lack of Nbeal2 affects transport and accumulation of granules in the 
proplatelet buds. To this end we carried out proplatelet assays using mature culture-derived 
MKs as described above and visualised the proplatelet buds by scanning electron microscopy 
(SEM), TEM and confocal microscopy (Fig 5A-K). This confirmed the presence of α-
granules at different levels of maturation, including MVBs within the cytoplasm of the 
proplatelet territories in both control and Nbeal2-/- samples (Fig 5A-C). Immunolabelling for 
VWF showed the typical granular distribution previously documented but in particular 
comparable accumulation of α-granules in the proplatelet buds in both sets of samples (Fig 
5D-E). The α-granule content is the result of both intracellular protein synthesis and 
endocytosis of extracellular proteins, such as fibrinogen. To assess whether the lack of 
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Nbeal2 potentially affects the latter cellular process, MKs were incubated with FITC-labelled 
fibrinogen for 24 hours during culture prior to performing the proplatelet assay. FITC-
fibrinogen showed a similar granular distribution to that seen for VWF, not only in the core 
of the cells but also in the proplatelet buds (Fig 5F-G). Co-immunolabelling with other α-
granule proteins of endogenous origin, namely P-selectin (Fig 5H-I) and VWF (Fig 5J-K) 
confirmed that both endogenous and endocytosed proteins accumulate in granules within the 
terminal buds of both control and Nbeal2-/- proplatelets, although segregating in distinct 
population of granules, a phenomenon which has been previously described 27. Additional 
deconvolved images of the raw confocal stacks were also generated and are available for 
viewing (Suppl Fig 7 and 8). The number of proplatelets and VWF+ proplatelet buds per cell 
were quantified and revealed no statistically significant differences (Fig 5L-M). 
 
Nbeal2-/- MKs have a proinflammatory profile 
Both GPS mice and patients develop premature myelofibrosis of the bone marrow with 
ageing and it may be that this is caused by the pro-inflammatory nature of GPS MKs and 
platelets. To provide insights into the role of Nbeal2 in MKs, we analysed the RNA from 
culture-derived MKs on gene expression arrays. Analysis showed that 157 genes were 
differentially expressed with a False Discovery Rate < 0.1. The 25 most differentially 
expressed transcripts (over-expressed and under-expressed in Nbeal2-/-) are listed in Suppl 
File 2. Absence of Nbeal2 was confirmed at the transcript level. Term enrichment analysis 
based on Gene Ontology (GO) molecular function identified 20 gene sets significantly 
enriched in Nbeal2-/- relative to control MKs (FDR < 0.25) (Suppl File 3). The most 
significant GO term enrichment concerned genes encoding chemokines (Fig 6A). A set of 
chemokine transcripts (namely Ccl3, Ccl4, Cxcl16, Cxcl1, Cxcl2 and Cxcl10) was selected 
for confirmation testing of the observed transcript level differences by qPCR and all 
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replicated (Fig 6B). Ccl3 and Ccl4 encode Macrophage Inflammatory Protein (MIP) 1α and 
1β, respectively, well-known pro-inflammatory chemokines increased in primary 
myelofibrosis 28,29, whilst Cxcl1 is a neutrophil chemoattractant30. To determine whether the 
increased transcript levels were mirrored at the protein level, levels of MIP1α, MIP1β and 
Cxcl1 were determined by ELISA in MK culture supernatant and plasma. MIP-1α and MIP-
1β levels were higher in the culture supernatant of Nbeal2-/- MKs (Fig 6C), and MIP-1β was 
significantly increased (P-value=0.0019) in plasma of Nbeal2-/- animals at 1 year of age when 
compared to age-matched controls (Fig 6D).  
 
Alpha-granule deficiency confers protection against cancer metastasis 
Platelet function extends beyond hemostasis and we therefore went on to analyze the 
potential relevance of platelet α-granules in tumorigenesis, and, in particular, metastatic 
spread. For this we used an in vivo model of experimental lung metastasis. Ten days after 
intravenous injection of murine melanoma B16-F10 cells, lung metastases were quantified. 
Strikingly, we found a marked reduction, by almost 80%, in the number of pulmonary 
metastases in Nbeal2-/- mice (231±21 vs 56±21, P-value= 0.001) (Fig 7). To confirm the key 
role of platelets and particularly the role of α-granules in metastasis, platelets isolated from 
control mice were transfused into Nbeal2-/- animals prior to injecting the melanoma cells. The 
platelet count incremented by 119±20x109/L (P-value<0.05) compared to mice injected with 
PBS alone and was maintained over the first 48 hours post-transfusion. One of the mice 
transfused with PBS had to be culled at day 6 and showed no lung metastases. At day10, 
PBS-control mice had 115±18 pulmonary metastases, while platelet-transfused and PBS-
injected Nbeal2-/- animals had 95±7 and 8±3, respectively (P-value = 0.004).  
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Discussion  
For over 40 years cellular and biological studies of GPS have been carried out using human 
samples from clinical cases and therefore most of the reported data relates to the platelet 
phenotype, due to challenges in isolating abundant MKs from human blood samples. In 2011, 
three groups reported NBEAL2 as the gene underlying GPS, and consequently, two reports 
have been recently published describing an Nbeal2-/- mouse model that recapitulates the 
platelet phenotype observed in human GPS cases 31,32. Although our study uses a novel 
Nbeal2-/- mouse with a different genetic strategy, the platelet hallmarks of GPS are 
recapitulated. In addition we present data that provides a role for Nbeal2 in platelets beyond 
their classical hemostatic role. We demonstrate that the lack of α-granules in platelets is the 
result of an impaired retention rather than a lack of granule generation. In addition, we show 
that Nbeal2 deficiency in MKs leads to distinctive pathological findings such as 
myelofibrosis and a pro-inflammatory phenotype. 
In agreement with previous studies 31,32, the hemostatic platelet function of Nbeal2-/- mice 
was shown to be similarly impaired. In one study, this was shown to correlate with a decrease 
in the thrombo-inflammatory process of hypoxic brain damage in and impaired wound 
healing suggesting an effect of platelet α-granule deficiency beyond primary hemostasis. In 
contrast with the previous mouse models, we observed the development of bone marrow 
fibrosis and splenomegaly (a feature of human GPS) in older animals. It is well documented 
that, in the context of myeloproliferative neoplasms (MPNs), pro-inflammatory cytokines 
play a central role in clinical symptoms and, probably, pathogenicity of the disease 29. In the 
context of JAK2V617F positive myelofibrosis, one of the main benefits of treating patients 
with JAK2 inhibitors has been the control of inflammation and the raised cytokine levels 
leading to a resolution of systemic symptoms 33. Transcriptome analysis of cultured MKs 
 15
followed by qPCR validation clearly showed that Nbeal2-/- MKs overexpress transcripts for 
several chemokines confirming a link between Nbeal2 deficiency and inflammation in the 
context of GPS. Significantly, we found that plasma levels of at least one of those 
chemokines (MIP-1β) were raised suggesting a potential systemic effect beyond the bone 
marrow. Emperipolesis of neutrophils was a prominent feature of the Nbeal2-/- marrow, 
which may be explained through the paracrine effect of chemoattractants such as Cxcl1 
released by Nbeal2-/- MKs. There is evidence in MPNs that emperipolesis can be driven by an 
increased level of P-selectin exposure on the surface of MKs which we did not observe in 
Nbeal2-/- MKs and that emperipolesis may induce MK death leading to the release of granule 
content and subsequent fibrosis 34. However, immunolabelling of cleaved Caspase-9 and Bcl-
XL in bone marrow showed no differences between mice suggesting that this may not be the 
case in the context of GPS. Although we cannot rule out that immune cells within the bone 
marrow participate in the inflammatory phenotype, overproduction of chemokines by MKs in 
liquid cultures depleted of inflammatory cells suggest that the MKs are one of the primary 
drivers of inflammation in GPS.  
Myelofibrosis in GPS patients may be the result of spontaneous release of α-granule proteins 
from the MKs 18. One of our most striking observations was the contrast between the 
circulating platelets, which were almost entirely devoid of α-granules, and the MKs where 
granule content was preserved. Analysis of the MKs by electron microscopy and 
immunofluorescence showed normal production/maturation of MVBs and mature α-granules, 
preserved packaging of both endogenous and endocytosed granule proteins and normal 
transport of the α-granules to the proplatelet tips. This indicates that the lack of Nbeal2 does 
not hamper granule synthesis but suggests lack of retention of α-granules within the cell. It is 
unclear whether this loss occurs in platelets after their release into the circulation and/or at 
the level of the MKs within the bone marrow. If the latter, the loss can be compensated by de 
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novo synthesis explaining the similar granule content in control and Nbeal2-/- MKs. We 
measured plasma concentration of granule proteins such as VWF and fibrinogen and found 
no difference between Nbeal2-/- and control samples (data not shown) which was also 
reported in previous studies 31,32 but this does not exclude a paracrine effect of the “leaking” 
granule proteins within the bone marrow potentially contributing to the pro-inflammatory 
effects of the MKs mentioned above and the development of myelofibrosis. 
The observation of α-granules within the Nbeal2-/- MKs is in contrast with the previously 
published mouse studies, which used a different knock-down strategy to our own. We can 
however draw a parallel to the few reported studies of MKs isolated from humans with GPS: 
some studies report the absence of α-granules in the MKs 35,36 whilst others showed the 
presence of abnormal α-granules in the MKs by immunolabelling 37 further confirmed by EM 
38
. Indeed, Suppl Fig 9 illustrates MKs from a patient with GPS (carrying the mutation L388P 
in NBEAL2) that does contain granules just as it is the case for the mouse MKs reported here. 
One possible explanation for these differences would be sample preparation and in particular 
the level of maturity of the MKs analysed (culture-derived vs extracted from bone marrow, 
immature cells vs proplatelet forming MKs). We cannot rule out that these differences are 
explained by the variation in genotype between patients. Mutations in human NBEAL2 have 
been found to affect different domains of the NBEAL2 protein, which may lead to a spectrum 
of phenotypes within the MKs whilst the end product, the platelets, is universally depleted of 
α-granules. A better understanding of the hitherto unknown function of the NBEAL2 protein 
and of its partners will be crucial in shedding light on how its deficiency/dysfunction affects 
α-granule formation and retention within the cell. 
The clear demonstration that a lack of platelet α-granules has a link with a non-hemostatic 
platelet function led us to investigate whether the same was true for the role of platelets in 
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malignancies. To this end we used an in vivo model of cancer metastasis. Although this 
model addresses chiefly homing and invasion of malignant cells into tissue in the somewhat 
artificial context of large numbers of cells directly injected into the blood stream, the striking 
data place the platelet, and in particular its α-granules, at the center of the metastatic process. 
The rate of metastasis was markedly decreased in Nbeal2-/- animals but remarkably, although 
transfusion with 240x106 platelets only raised the platelet count by up to 15% of the Nbeal2-/- 
baseline count, the rate of metastasis was almost restored to the levels observed in control 
mice. This observation makes it unlikely that the reduction in the platelet count of the Nbeal2-
/-
 mice is responsible for the decreased in metastasis observed but rather that it is their 
qualitative difference i.e. absence of a-granules that is the root cause for these results. The 
role of platelets in the spread of solid tumors is abundantly proven and different mechanisms 
have been put forward to explain this 39. Clinical implications of this phenomenon have been 
clearly demonstrated in a recent study showing a protective effect of low-dose “anti-platelet” 
aspirin for colon cancer 7. P-selectin has been shown to be a key mediator in the formation of 
platelet-tumor cell aggregates promoting tumor metastasis 40-43, and, P-selectin deficient mice 
are protected against cancer spread 44-46. The lack of P-selectin expression on the surface of 
activated Nbeal2-/- platelets provides a plausible explanation for the observation reported 
here, although we cannot exclude that other factors such as the lack of growth factors and 
pro-angiogenic proteins normally stored in the platelet α-granules could play a role. The 
majority of platelet transfusions to patients are carried out in the context of cancer treatment. 
The generation of platelets in vitro for clinical use is fast becoming a real prospect 47. It is not 
impossible to consider that informed by such models as described here, we could genetically 
modify stem cells so that their platelet progeny contain granules that preserve their 
haemostatic function whilst lowering their positive effect on metastasis 48. 
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In conclusion, we show that the pathogenicity of GPS extends beyond the absence of α-
granules and a platelet hemostatic defect. We demonstrate an inflammatory component to the 
disease mediated, at least in part, by MKs, reflected by the development of myelofibrosis in 
older animals. We show evidence that Nbeal2 deficiency does not play a role in granule 
formation as such but in their retention within the MKs and platelets. Finally, we demonstrate 
in this mouse model for the first time a role for platelet α-granules in the metastatic spread of 
solid tumors. 
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Figure Legends 
 
Figure 1. Deficiency of Nbeal2 in mice leads to Gray Platelet Syndrome. (A) Transcript 
levels of Nbeal2 by qPCR in RNA isolated from in vitro-cultured megakaryocytes. Results 
are normalised to levels of GP6 (n=3). (B) Protein levels of Nbeal2 in platelets and 
megakaryocytes from Nbeal2-/- and control mice. β-actin included as an internal loading 
control (n=3). (C) Platelet count in Nbeal2-/- and control animals (n=13). (D) Mean platelet 
volume in Nbeal2-/- and control mice (n=13). (E) Size distribution of the gated platelet 
population visualised in a representative flow cytometry histogram (Forward-scatter). (F) 
Representative May-Grünwald Giemsa stain of blood smears. Arrows indicate the presence 
of platelets. Platelets are larger and appear grey in Nbeal2-/- samples. Scale bar: 20 μm. (G) 
Different degrees of splenomegaly were observed in Nbeal2-/- mice beyond the age of 9 
months. Age-matched control mice were used for comparison (n=4). (H) A representative 
reticulin staining of bone sections from mice at 9 months of age showing myelofibrosis in 
Nbeal2-/- marrow. Scale bar: 200 μm.  
 
 
Figure 2. Impaired platelet function in Nbeal2-/- mice. (A,B) Ultrastructure of platelets 
from control mice showing abundant α-granules (AG), among other organelles. (C,D) 
Ultrastructure of Nbeal2-/- platelets showing a significant reduction of α-granules, several 
vacuoles (V) and membrane inclusions (MI). (E-F) Immunolabelling of VWF (red) and 
CD41 (green) in control (E) and Nbeal2-/- (F) platelets. Images correspond to the maximum 
intensity projections of an image stack across an entire platelet section. A higher 
magnification of the circled platelets is shown for clarification. VWF is restricted to the α-
granules in control platelets while its distribution is more diffuse in Nbeal2-/- platelets. Note 
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also the absence of VWF in some Nbeal2-/- platelets. (G) Representative immunoblots of α-
granule proteins von Willebrand Factor (VWF), thrombospondin-1 (THBS1) and platelet 
factor 4 (PF4) in control and Nbeal2-/- platelet lysates. CD63 (LAMP-3), a lysosomal/dense 
granule marker, and β-actin and GAPDH included as loading controls. Bottom graphs show 
the densitometry analysis performed using ImageJ (n=3). (H) Flow cytometry analysis of 
platelet activation induced by 1 μg/mL collagen-related peptide (CRP) and 1 U/mL thrombin 
(n=4) showing equivalent fibrinogen binding to Nbeal2-/- and control platelets (top panel, 
only shown for CRP), in contrast reduced P-selectin exposure in Nbeal2-/- platelets with both 
agonists (middle and bottom panels). Plots with vertical lines correspond to basal platelet 
activation in the absence of agonist. For all graphs, bars represent mean±SEM. N.S.: non-
significant. MFI: Mean Fluorescent Intensity. Scale Bar: 100 nm (A, C) and 500 nm (B, D). * 
P-value<0.05. 
 
 
Figure 3. Abnormal MK maturation in Nbeal2-/- mice. (A) CD41 labelling and H&E 
staining of bone sections (60x) in control and Nbeal2-/- mice. Arrows point at MKs. Two 
representative large polyploid MKs are shown in the bottom panels at high magnification 
(100x). Note the presence of leukocytes (L) within MKs (emperipolesis) at high 
magnification (100x) in the Nbeal2-/- samples. (B) Quantitation of MKs in bone sections from 
A (5 different fields in 5 mice). Similar total MK numbers in control and Nbeal2-/- mice (top 
panel) but the numbers of large MKs with more than 2 nuclear lobes (middle panel) and 
numbers of small MKs with 2 or less nuclear lobes (bottom panel) are significantly different 
in Nbeal2-/- mice. (C) Percentage of CD41+ cells in bone marrow cultures in the presence of 
thrombopoietin (TPO) (1 and 5 ng/mL) at different time points (1, 3 and 5 days) (n=4). (D) 
Ploidy profile of CD41+ cells at day 3 (n=4). (E) Percentage of proplatelet forming 
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megakaryocytes upon adhesion to fibrinogen of cultured megakaryocytes purified by BSA 
gradient (n=4). For all graphs, bars represent mean±SEM. * p<0.05.  
 
Figure 4. Ultrastructure and protein analysis of megakaryocytes. (A-D) Ultrastructure of 
culture-derived megakaryocytes from control (A) and Nbeal2-/- (B) mice at low magnification 
(A, B) and high magnification (C, D), respectively. Multivesicular bodies (MVB), precursors 
of α-granules, are present in both control and Nbeal2-/- megakaryocytes. (E, F) Ultrastructure 
of bone marrow megakaryocytes in control and Nbeal2-/- animals at low magnification. (G, 
H, I, J) Ultrastructure of bone marrow megakaryocytes from control and Nbeal2-/- mice at 
high magnification. A well-defined demarcation membrane system with the presence of 
platelet territories and α-granules (AG) in control cells (G, I). The demarcation membrane 
system in Nbeal2-/- megakaryocytes is not well-defined (H, J), however, α-granules (AG) are 
present. (K) Low magnification of a proplatelet-forming MK from Nbeal2-/- bone marrow. 
(L) A high magnification of the circled area in K highlights the presence of α-granules (AG) 
inside the emerging platelet fields, and vacuoles (V) within the MK cytoplasm. (M) 
Representative immunoblots of α-granule proteins (VWF, thrombospondin-1 and PF4) in 
control and Nbeal2-/- MKs. CD63 (LAMP-3), a lysosomal/dense granule marker, and β-actin 
and GAPDH included as loading controls. Below, graphs show the densitometry analysis 
performed using ImageJ (n=3). Bars represent mean±SEM. N.S.: non-significant. Scale bar: 2 
μm (A, B, E, F, K), 500 nm (C, D, G, H, I, J, L). Representative images were selected from 5 
different mice per group. 
 
Figure 5. Analysis of α-granules and their content in proplatelet-forming 
megakaryocytes by electron and confocal microscopy. (A) Low magnification of a 
representative control proplatelet-forming megakaryocyte by SEM showing proplatelet-like 
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territories emerging from the main core of the cell. (B, C). Higher magnification of the 
circled areas in A seen by TEM. The developing proplatelets contain multivesicular bodies 
(MVB), precursors of α-granules. (D, E) Immunolabelling of CD41 and VWF in proplatelet-
forming megakaryocytes by confocal microscopy in control (D) and Nbeal2-/- (E) cells. VWF 
is restricted to the multivesicular bodies observed in B and C. The inset at the top-right corner 
in E highlights the presence of a thin MK filament bridging several emerging platelet-like 
particles. (F, G) Immunolabelling of CD41 in proplatelet-forming megakaryocytes previously 
cultured in the presence of FITC-Fibrinogen. Fibrinogen is endocytosed and packaged into α-
granules in control (F) and Nbeal2-/- (G) megakaryocytes, and transported through the 
proplatelet shafts. (H, I) Proplatelet-forming megakaryocytes cultured with FITC-Fibrinogen 
as stated in F, and P-selectin-immunolabelled in control (H) and Nbeal2-/- (I) samples. (J, K) 
Proplatelet-forming megakaryocytes cultured in the presence of FITC-fibrinogen as stated in 
F, and VWF-immunolabelled in control (J) and Nbeal2-/- (K) samples. (L) Quantitation of 
proplatelets bud in MK culture. (M) Percentage of proplatelets buds containing the α-granule 
protein VWF. For each panel, the insets represent a higher magnification of platelet-like 
particles showing a similar granular distribution of P-selectin, VWF and fibronogen in 
control and Nbeal2-/- cells. For panels D-K, the nucleus was stained with DAPI (blue). 
Representative images were selected from 5 different mice per group. 
 
 
Figure 6. Gene expression array in culture-derived megakaryocytes. (A) Enrichment of 
the “Chemokine activity” gene set in Nbeal2-/- megakaryocytes with the genes contributing to 
this enrichment. (B) Fold change of the 6 most significant genes identified in A in Nbeal2-/- 
versus control MKs generated by q-PCR using different samples as those used in the array 
(n=3). (C) Plasma levels of the chemokines MIP-1α (Ccl3), MIP-1β (Ccl4) and Cxcl1 in MK 
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culture supernatant. (D) Levels of these chemokines in plasma of control and Nbeal2-/- mice 
(n=5). Bars represent mean±SEM. * p<0.05. 
 
Figure 7. Reduced metastasis in Nbeal2-/- mice. Lung metastasis was induced by tail vein 
injection of 5 x 105 mouse melanoma B16-F10 cells. Lungs were taken after 10 days and the 
number of pulmonary metastases counted on all 5 lobes of the lung. Representative lung 
metastases in control (n=9) and Nbeal2-/- mice (n=5) (left panel) and quantitation (right 
panel). Bars represent mean±SEM. * p=0.0001. 
 







